Opinion|Videos|November 3, 2023
Future Perspectives in the Treatment of Advanced RCC
Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.
The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.
Obesity may increase breast cancer risk partly by removing a natural defense.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
2
Bexobrutideg Produces High Response Rates Across Treatment Lines in CLL/SLL
3
FDA Grants Fast Track Designation to Pan-KRAS Inhibitor KST-6051 in KRAS-Mutant Solid Tumors
4
FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis
5